Attention Deficit Hyperactivity Disorder
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Attention Deficit Hyperactivity Disorder is a moderately active landscape with 89 programs across 49 companies. The most active players are Sumitomo Pharma America, Inc., Chelsea Therapeutics, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. 38 therapies are approved with 19 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Sumitomo Pharma America, Inc.
1 program
Chelsea Therapeutics
1 program
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
1 program
Glaxo Dba Glaxosmithkline
1 program
New River Pharmaceuticals
2 programs
Addrenex Pharmaceuticals, Inc.
2 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
97%
Small molecule
98 of 101 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 101 classified programs, each share of the total. Modality classified for 98% of 103 pipeline programs.
Analysis
Trial Status
211
clinical trials
Clinical Trials
Trial Activity
211 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)